Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Colorcon
Harvard Business School
Boehringer Ingelheim
Fuji
Accenture
Queensland Health
Cantor Fitzgerald

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206321

« Back to Dashboard

NDA 206321 describes SAXENDA, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug. Additional details are available on the SAXENDA profile page.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the liraglutide recombinant profile page.
Summary for 206321
Tradename:SAXENDA
Applicant:Novo Nordisk Inc
Ingredient:liraglutide recombinant
Patents:16
Formulation / Manufacturing:see details
Pharmacology for NDA: 206321
Medical Subject Heading (MeSH) Categories for 206321
Suppliers and Packaging for NDA: 206321
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321 NDA Novo Nordisk 0169-2800 0169-2800-15 5 SYRINGE, PLASTIC in 1 CARTON (0169-2800-15) > 3 mL in 1 SYRINGE, PLASTIC
SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321 NDA Novo Nordisk 0169-2800 0169-2800-90 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-90) > 3 mL in 1 SYRINGE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength18MG/3ML (6MG/ML)
Approval Date:Dec 23, 2014TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 22, 2022Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Patent:➤ Sign UpPatent Expiration:Jan 1, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Aug 13, 2025Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 206321

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 ➤ Sign Up ➤ Sign Up
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Chubb
Farmers Insurance
Dow
Argus Health
McKesson
Fuji
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.